Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
2.525
-0.005 (-0.20%)
Nov 21, 2024, 3:08 PM EST - Market open
Cardiff Oncology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 0.69 | 0.49 | 0.39 | 0.36 | 0.37 | 0.24 | Upgrade
|
| Revenue Growth (YoY) | 49.57% | 26.42% | 7.52% | -1.91% | 49.61% | -35.34% | Upgrade
|
| Cost of Revenue | 34.9 | 32.86 | 27.11 | 17.38 | 11.24 | 11.16 | Upgrade
|
| Gross Profit | -34.22 | -32.37 | -26.72 | -17.02 | -10.87 | -10.92 | Upgrade
|
| Selling, General & Admin | 12.2 | 13.04 | 13.18 | 11.84 | 8.22 | 5.76 | Upgrade
|
| Operating Expenses | 12.2 | 13.04 | 13.18 | 11.84 | 8.22 | 5.76 | Upgrade
|
| Operating Income | -46.41 | -45.41 | -39.9 | -28.86 | -19.09 | -16.68 | Upgrade
|
| Interest Expense | - | - | - | - | -0 | - | Upgrade
|
| Interest & Investment Income | 3.48 | 4.07 | 1.58 | 0.26 | 0.09 | 0.23 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.05 | -0.1 | -0.38 | 0.3 | -0.31 | 0.03 | Upgrade
|
| EBT Excluding Unusual Items | -42.98 | -41.44 | -38.7 | -28.29 | -19.31 | -16.41 | Upgrade
|
| Pretax Income | -42.98 | -41.44 | -38.7 | -28.29 | -19.31 | -16.41 | Upgrade
|
| Net Income | -42.98 | -41.44 | -38.7 | -28.29 | -19.31 | -16.41 | Upgrade
|
| Preferred Dividends & Other Adjustments | 0.02 | 0.02 | 0.02 | 0.02 | 3.29 | 0.29 | Upgrade
|
| Net Income to Common | -43.01 | -41.47 | -38.73 | -28.32 | -22.6 | -16.71 | Upgrade
|
| Shares Outstanding (Basic) | 45 | 45 | 44 | 39 | 21 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 45 | 45 | 44 | 39 | 21 | 6 | Upgrade
|
| Shares Change (YoY) | 1.40% | 2.47% | 11.71% | 86.97% | 249.44% | 156.37% | Upgrade
|
| EPS (Basic) | -0.95 | -0.93 | -0.89 | -0.73 | -1.08 | -2.80 | Upgrade
|
| EPS (Diluted) | -0.95 | -0.93 | -0.89 | -0.73 | -1.08 | -2.80 | Upgrade
|
| Free Cash Flow | -34.65 | -31.47 | -34.83 | -23.25 | -16.53 | -13.34 | Upgrade
|
| Free Cash Flow Per Share | -0.77 | -0.70 | -0.80 | -0.60 | -0.79 | -2.23 | Upgrade
|
| Operating Margin | -6745.78% | -9305.74% | -10337.31% | -8037.60% | -5214.75% | -6817.79% | Upgrade
|
| Profit Margin | -6250.73% | -8496.93% | -10033.16% | -7887.19% | -6174.32% | -6829.31% | Upgrade
|
| Free Cash Flow Margin | -5036.77% | -6448.57% | -9022.28% | -6474.93% | -4515.30% | -5451.09% | Upgrade
|
| EBITDA | -46 | -45.01 | -39.67 | -28.4 | -18.62 | -16.18 | Upgrade
|
| D&A For EBITDA | 0.41 | 0.4 | 0.24 | 0.45 | 0.47 | 0.49 | Upgrade
|
| EBIT | -46.41 | -45.41 | -39.9 | -28.86 | -19.09 | -16.68 | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 0.24 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.